Thrombolytic Science, LLC (TSI), a clinical stage vascular health company developing biotechnology products to treat thrombotic diseases such as heart attacks and stroke, today announced that it will present at the 15th Anglo Nordic Life Science Investor Conference being held in London, May 24, 2018.

TSI recently completed of a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy mimicking nature’s safe and efficient fibrinolytic system, which is aimed at the treatment of clot-induced diseases. The first-in-man randomized, double-blind, placebo-controlled study demonstrated the overall safety and tolerability of TS01 in healthy adults. The Company is now preparing to enter human proof of concept trials in ischemic stroke and myocardial infraction.

Alexis C. Wallace, M.Sc.Eng., MBA, President and Chief Executive Officer of TSI will provide an update on TSI's clinical development programs and strategic plans. 

Details of the presentation are as follows:

 Event:Anglo Nordic Life Science Investor Conference

 Date:Thursday, May 24th, 2018

 Time:3:30 p.m.

 Location:The Biotech Investment Room, County Hall, Riverside Building, Belvedere Road, London SE1 7PB

About TSI
TSI is a privately-held vascular health and biotechnology company currently developing a new-generation bio-inspired clot-dissolving therapy. TSI intends to develop treatments for ischemic stroke, heart attacks and other clot-induced diseases. TSI’s technology is based upon pioneering earlier work on proUK by the Vascular Research Laboratory. 

About TS01
TS01 is a proprietary new-generation, clot-dissolving therapy for the treatment of patients with ischemic stroke, heart attacks and other thrombotic diseases. HisproUK, TS01’s main component, is a proprietary, rationally designed, single-site mutant of native proUK. TS01 selectively targets occlusive clots that cause strokes and heart attacks.

Register as Visitor to CPhI China 2018!